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In our country, groups of rare diseases are not rare, but rare disease groups of the 
social security system is rare. About 10000000 groups of rare diseases in China, 
involving millions of families. Rare disease groups in China are mostly free in the 
medical security system, with rare disease groups is not only difficult to cure there are 
endless disease, poverty and loneliness. Rare disease worldwide there have been as 
many as 6000 kinds of rare disease groups, indeed, personalized, special, complex 
medical needs, there are some difficulties in the supply, but the research and practice 
of the international community has fully showed rare disease groups into the social 
medical insurance an effective way to meet the medical needs of the rare disease 
groups. From the medical insurance function value, national identity, civil rights and 
protection of the rare disease groups may choose, social medical insurance is satisfied 
The essential and main way of the medical needs of patients with rare diseases . 
The rare disease groups into the medical insurance need to have national health 
public financial support, effective cognition, perfect social condition and other social 
foundation. Specifically, China has basically have universal health coverage, multiple 
social security NGO, people have a certain understanding of conditions on the rare 
disease, but rare disease in aspects of legislation, Abraham drug related protection is 
not sufficient. But with some domestic provinces to try and effect from the 
development trend of society, all obstacles will therefore be smoothly done or easily 
solved the rare disease groups, into the social medical insurance system in China is 
feasible. The basic situation of our country, rare disease groups should adopt the mode 
of social medical insurance "inclusive indulgence" mode, and increase the internal 
co-ordination of rare disease groups based on localized management as supplementary 
medical insurance, and orphan drugs into the medical insurance reimbursement name 
In the book, will be included in a rare disease to a serious illness insurance system, 















participate in the construction of multi channel security system. In addition, to 
accelerate the process of legislation, strengthen government support in policy and 
resources. The development of a professional directory of rare diseases, and 
vigorously develop civil rare disease organizations, truly multi-channel protection. 
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